Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are ...

Hulu’s television adaptation of Margaret Atwood’s landmark 1985 feminist novel, The Handmaid’s Tale, has now come to an end.

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Kimberly-Clark will sell a majority of the unit to Brazil's Suzano, the big pulp producer. Winnebago Industries said it expects to adjust its headcount, shift production plans and post ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

O-T Fagbenle has been gracing American film and television screens since the early aughts with I Could Never Be Your Woman, ...